Zions Bancorporation National Association UT Has $2.74 Million Position in Medpace Holdings, Inc. $MEDP

Zions Bancorporation National Association UT lowered its holdings in Medpace Holdings, Inc. (NASDAQ:MEDP) by 19.6% in the 4th quarter, HoldingsChannel.com reports. The firm owned 4,886 shares of the company’s stock after selling 1,189 shares during the quarter. Zions Bancorporation National Association UT’s holdings in Medpace were worth $2,744,000 as of its most recent SEC filing.

Several other hedge funds have also bought and sold shares of the business. Illinois Municipal Retirement Fund grew its position in Medpace by 67.6% in the 4th quarter. Illinois Municipal Retirement Fund now owns 2,408 shares of the company’s stock valued at $1,352,000 after purchasing an additional 971 shares during the period. Deutsche Bank AG boosted its holdings in Medpace by 0.7% during the 4th quarter. Deutsche Bank AG now owns 6,948 shares of the company’s stock worth $3,902,000 after acquiring an additional 49 shares during the last quarter. Motley Fool Asset Management LLC boosted its holdings in Medpace by 5.0% during the 4th quarter. Motley Fool Asset Management LLC now owns 866 shares of the company’s stock worth $486,000 after acquiring an additional 41 shares during the last quarter. Focus Partners Advisor Solutions LLC boosted its holdings in Medpace by 24.6% during the 4th quarter. Focus Partners Advisor Solutions LLC now owns 5,592 shares of the company’s stock worth $3,141,000 after acquiring an additional 1,105 shares during the last quarter. Finally, Waddell & Associates LLC boosted its holdings in Medpace by 62.6% during the 4th quarter. Waddell & Associates LLC now owns 1,455 shares of the company’s stock worth $817,000 after acquiring an additional 560 shares during the last quarter. Institutional investors and hedge funds own 77.98% of the company’s stock.

Analyst Ratings Changes

MEDP has been the topic of a number of analyst reports. Barclays cut their price objective on shares of Medpace from $500.00 to $450.00 and set an “equal weight” rating on the stock in a report on Friday, April 24th. Leerink Partners cut their price objective on shares of Medpace from $575.00 to $485.00 and set a “market perform” rating on the stock in a report on Wednesday, February 11th. Weiss Ratings downgraded shares of Medpace from a “buy (b-)” rating to a “hold (c+)” rating in a report on Monday, April 6th. Mizuho set a $582.00 price objective on shares of Medpace in a report on Wednesday, February 11th. Finally, Jefferies Financial Group raised shares of Medpace from a “hold” rating to a “buy” rating and set a $560.00 price objective on the stock in a report on Friday, February 13th. Four equities research analysts have rated the stock with a Buy rating, ten have assigned a Hold rating and one has given a Sell rating to the stock. According to MarketBeat.com, the company currently has a consensus rating of “Hold” and an average target price of $467.08.

Insider Transactions at Medpace

In related news, General Counsel Stephen P. Ewald sold 16,349 shares of the business’s stock in a transaction dated Thursday, May 28th. The shares were sold at an average price of $450.00, for a total value of $7,357,050.00. Following the transaction, the general counsel directly owned 20,343 shares of the company’s stock, valued at approximately $9,154,350. The trade was a 44.56% decrease in their position. The sale was disclosed in a filing with the Securities & Exchange Commission, which can be accessed through this hyperlink. Also, President Jesse J. Geiger sold 31,707 shares of the business’s stock in a transaction dated Tuesday, March 17th. The stock was sold at an average price of $455.30, for a total transaction of $14,436,197.10. Following the completion of the transaction, the president directly owned 15,000 shares in the company, valued at $6,829,500. This trade represents a 67.88% decrease in their ownership of the stock. The SEC filing for this sale provides additional information. 20.50% of the stock is currently owned by insiders.

Medpace Stock Performance

Shares of NASDAQ:MEDP opened at $465.73 on Thursday. The company’s 50-day moving average is $456.97 and its 200 day moving average is $505.72. The company has a market capitalization of $13.30 billion, a P/E ratio of 29.27, a price-to-earnings-growth ratio of 2.37 and a beta of 1.18. Medpace Holdings, Inc. has a fifty-two week low of $294.07 and a fifty-two week high of $628.92.

Medpace (NASDAQ:MEDP) last issued its quarterly earnings results on Wednesday, April 22nd. The company reported $4.28 earnings per share for the quarter, topping analysts’ consensus estimates of $3.74 by $0.54. The company had revenue of $706.60 million for the quarter, compared to the consensus estimate of $697.82 million. Medpace had a net margin of 17.19% and a return on equity of 120.89%. The firm’s quarterly revenue was up 26.5% on a year-over-year basis. During the same period in the previous year, the firm earned $3.67 EPS. Medpace has set its FY 2026 guidance at 16.680-17.500 EPS. As a group, research analysts predict that Medpace Holdings, Inc. will post 17.04 earnings per share for the current year.

About Medpace

Medpace Holdings, Inc (NASDAQ: MEDP) is a global contract research organization (CRO) that provides comprehensive clinical development services to biotechnology, pharmaceutical and medical device companies. The company supports clinical trials across all phases (I–IV), offering end-to-end solutions designed to streamline the development process and accelerate the delivery of new therapies to market.

Medpace’s core service offerings include clinical pharmacology, regulatory affairs consulting, project management, central laboratory services, imaging, data management and biostatistics, pharmacovigilance and medical writing.